Fig. 1: Establishment and characterization of a mouse model of HSV-1 seropositivity. | npj Vaccines

Fig. 1: Establishment and characterization of a mouse model of HSV-1 seropositivity.

From: Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity

Fig. 1

a Female (closed symbols) and male (open symbols) C57BL6 mice were infected intranasally with 5 × 104 pfu/mouse of HSV-1 B3 × 1.1. Mice were monitored over 20 days for signs of disease and distress. At day 14 post-primary challenge, mice were bled retro-orbitally to obtain immune serum, which was tested for b total HSV-1-specific IgG by ELISA (1:10,000 dilution) and c fold-induction of FcγRIV activation (mFcγRIV ADCC Reporter Bioassay, Promega). Data points are shown with symbols to indicate vaccination groups to which each mouse was subsequently assigned; the mean is indicated. Panel a, n = 75 females and 20 males; Panel b, n = 67 females and 16 males across four independent experiments.

Back to article page